Effect of bromfenac on free radical oxidation in model systems

Abstract


Aim. The study of free radical oxidation processes in an experiment on model systems using the anti-inflammatory drug bromfenac (nakwan) widely used in ophthalmology for the treatment of infectious and inflammatory diseases of the anterior chamber of the eye.

Methods. The antioxidant capacity of the drug was evaluated by chemiluminescence registration and analysis of model systems that generate reactive oxygen species and reproduce lipid peroxidation processes using the chemiluminomer CL-003. The following parameters of spontaneous and induced chemiluminescence were determined: light sum and maximum luminescence amplitude, duration of latent period, amplitude of fast and slow flash.

Results. When tested in vitro in two different model systems, a high antioxidant activity of the studied drug was established, up to complete suppression of chemiluminescence when 90 μg of bromfenac was added to the incubation medium, which characterizes the inhibition of the generation of reactive oxygen species. A significant increase in total antioxidant activity with bromfenac was also demonstrated, which is reflected by the integral parameter of chemiluminescence — light sum which decreased with the introduction of 10 μg of the drug by 1.2 times, and with 90 μg by 1.5 times. A comparative analysis of the antioxidant properties of various nonsteroidal anti-inflammatory drugs used in ophthalmic practice demonstrated a more pronounced efficacy of bromfenac compared to ketorolac, the use of which was not accompanied by statistically significant changes in chemiluminescence. A very important mechanism of the positive effect of bromfenac is the direct dependence of the action on its quantity in the reaction medium, which opens up prospects for the controlled correction of free radical phenomena and the excessive activation of lipid peroxidation in the imbalance of the pro- and antioxidant processes in biological systems.

Conclusion. It is suggested that the protective effects of the drug in various infectious-inflammatory lesions of the eye can be determined, along with previously known properties, its antioxidant activity, restriction of increased production of reactive oxygen species and oxidative stress phenomena.


E F Galimova

Bashkir State Medical University

Author for correspondence.
Email: efgalimova@mail.ru
Ufa, Russia

Z G Khaibullina

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

D A Enikeev

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

Yu L Bortsova

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

K S Mochalov

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

S Sh Galimova

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

O Yu Travnikov

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

T S Asadullina

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

K S Aver’yanova

Bashkir State Medical University

Email: efgalimova@mail.ru
Ufa, Russia

  1. Lebedev O.I., Surov A.V., Akent’eva E.V. Features of ophthalmic inflammatory diseases results of a federal study. Ophthalmologicheskie vedomosti. 2014; 7 (2): 13–17. (In Russ.)
  2. Rajpal R.K., Ross B., Rajpal S.D., Hoang K. Bromfenac ophthalmic solution for the treatment of postoperative ocular pain and inflammation: safety, efficacy, and patient adherence. Patient Preference and Adherence. 2014; 25 (8): 925–931. doi: 10.2147/PPA.S46667.
  3. Cho H., Wolf K., Wolf E. Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution. Clin. Ophthalmol. 2009; 3: 199–210. doi: 10.2147/OPTH.S4806.
  4. Hoy S. Bromfenac ophthalmic solution 0.07%: A review of its use after cataract surgery. Clin. Drug Invest. 2015; 35 (8): 525–529. doi: 10.1007/s40261-015-0309-3.
  5. Sheppard J., Cockrum P., Justice A., Jasek M. In vivo pharmacokinetics of Bromfenac ophthalmic solution 0.075%, Bromfenac ophthalmic solution 0.07%, and Nepafenac/Amfenac ophthalmic suspension 0.3% in rabbits. Ophthalmol. Therap. 2018; 7 (1): 157–165. doi: 10.1007/s40123-018-0130-1.
  6. Ohara K., Ohkubo A., Miyamoto T. et al. Prevention of miosis during cataract surgery by topical bromfenac sodium. Rinsho Ganka (Jpn. J. Clin. Ophthalmol.). 2004; 58: 1325–1328.
  7. Farkhutdinov R.R., Galimov Sh.N., Galimova E.F. Free radical oxi­dation in health and disease. Praktikuyushchiy vrach segodnya. 2010; 2: 54–61. (In Russ.)
  8. Aznabaev B.M., Yanbukhtina Z.R., Mukhamadeev T.R. et al. Effect of vital dyes for ophthalmic surgery on free-radical oxidation in model systems. Practicheskaya Meditsina. 2017; 2 (9): 12–15. (In Russ.)
  9. Ahuja M., Dhake A., Sharma S., Majumdar D. Topical ocular delivery of NSAIDs. AAPSJ. 2008; 10: 229–241. doi: 10.1208/s12248-008-9024-9.
  10. Walters T., Smyth-Medina R., Cockrum P. An ex vivo human aqueous humor-concentration comparison of two commercial bromfenac formulations. Clin. Ophthalmol. 2018; 12: 943–947. doi: 10.2147/OPTH.S170540.
  11. Jones B., Neville M. Nepafenac: an ophthalmic nonsteroidal antiinflammatory drug for pain after cataract surgery. Ann. Pharmacotherap. 2013; 47 (6): 892–896. doi: 10.1345/aph.1R757.
  12. Chinchurreta Capote A.M., Lorenzo Soto M., Rivas Ruiz F. et al. Comparative study of the efficacy and safety of bromfenac, nepafenac and diclofenac sodium for the prevention of cystoid macular edema after phacoemulsification. Intern. J. Ophthalmol. 2018; 11 (7): 1210–1216. doi: 10.18240/ijo.2018.07.22.

Views

Abstract - 18

PDF (Russian) - 24

Cited-By


PlumX


© 2019 Galimova E.F., Khaibullina Z.G., Enikeev D.A., Bortsova Y.L., Mochalov K.S., Galimova S.S., Travnikov O.Y., Asadullina T.S., Aver’yanova K.S.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.


Свидетельство о регистрации СМИ ЭЛ № ФС 77-75008 от 1 февраля 2019 года выдано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор)